SEC Info - American Renal Associates Holdings, Inc. - ‘10-Q’ for 3/31/20

Quarterly Report — Form 10-Q — Sect. 13 / 15(d) – SEA’34
Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 10-Q        Quarterly Report                                    HTML   1.19M 
 2: EX-31.1     Certification -- §302 - SOA'02                      HTML     30K 
 3: EX-31.2     Certification -- §302 - SOA'02                      HTML     30K 
 4: EX-32.1     Certification -- §906 - SOA'02                      HTML     24K 
 5: EX-32.2     Certification -- §906 - SOA'02                      HTML     24K 
76: R1          Cover Page                                          HTML     78K 
29: R2          Consolidated Balance Sheets                         HTML    135K 
21: R3          Consolidated Balance Sheets (Parenthetical)         HTML     47K 
45: R4          Consolidated Statements of Operations               HTML     88K 
74: R5          Consolidated Statements of Comprehensive Loss       HTML     41K 
27: R6          Consolidated Statement of Changes in Equity         HTML     91K 
19: R7          Consolidated Statements of Cash Flows               HTML    126K 
48: R8          Basis of Presentation and Organization              HTML     39K 
72: R9          Revenue                                             HTML     47K 
14: R10         Assets Held for Sale                                HTML     46K 
36: R11         Fair Value Measurements                             HTML    106K 
60: R12         Accrued Expenses and Other Current Liabilities      HTML     39K 
52: R13         Variable Interest Entities                          HTML     30K 
15: R14         Noncontrolling Interests Subject to Put Provisions  HTML     52K 
37: R15         Debt                                                HTML     85K 
61: R16         Leases                                              HTML    254K 
53: R17         Income Taxes                                        HTML     30K 
13: R18         Stock-Based Compensation                            HTML     73K 
38: R19         Loss Per Share                                      HTML     40K 
78: R20         Related Party Transactions                          HTML     45K 
50: R21         Commitments and Contingencies                       HTML     28K 
24: R22         Certain Legal and Other Matters                     HTML     50K 
32: R23         Changes in Ownership Interest in Consolidated       HTML     35K 
                Subsidiaries                                                     
79: R24         Recent and Subsequent Events                        HTML     43K 
51: R25         Basis of Presentation and Organization (Policies)   HTML     45K 
25: R26         Revenue (Tables)                                    HTML     34K 
33: R27         Assets Held for Sale (Tables)                       HTML     47K 
80: R28         Fair Value Measurements (Tables)                    HTML     98K 
49: R29         Accrued Expenses and Other Current Liabilities      HTML     40K 
                (Tables)                                                         
55: R30         Noncontrolling Interests Subject to Put Provisions  HTML     48K 
                (Tables)                                                         
64: R31         Debt (Tables)                                       HTML     52K 
35: R32         Leases (Tables)                                     HTML    187K 
12: R33         Stock-Based Compensation (Tables)                   HTML     69K 
54: R34         Loss Per Share (Tables)                             HTML     39K 
63: R35         Changes in Ownership Interest in Consolidated       HTML     36K 
                Subsidiaries (Tables)                                            
34: R36         Basis of Presentation and Organization (Details)    HTML     40K 
11: R37         Revenue (Details)                                   HTML     44K 
56: R38         ASSETS HELD FOR SALE - Narrative (Details)          HTML     44K 
62: R39         FAIR VALUE MEASUREMENTS - Schedule of fair values   HTML     73K 
                (Details)                                                        
43: R40         ASSETS HELD FOR SALE - Schedule of assets and       HTML     58K 
                liabilities held for sale (Details)                              
71: R41         FAIR VALUE MEASUREMENTS - Fair value rollforward    HTML     32K 
                for tax receivable agreement liability (Details)                 
31: R42         FAIR VALUE MEASUREMENTS - Narrative (Details)       HTML     31K 
23: R43         Accrued Expenses and Other Current Liabilities      HTML     43K 
                (Details)                                                        
41: R44         Variable Interest Entities (Details)                HTML     30K 
70: R45         Noncontrolling Interests Subject to Put Provisions  HTML     54K 
                (Details)                                                        
30: R46         DEBT - Schedule of long-term debt (Details)         HTML     50K 
22: R47         DEBT - Scheduled maturities of long-term debt       HTML     43K 
                (Details)                                                        
44: R48         DEBT - Narrative (Details)                          HTML    155K 
69: R49         LEASES - Narrative (Details)                        HTML     49K 
66: R50         LEASES - Lease Cost (Details)                       HTML     40K 
58: R51         LEASES LEASES - Supplemental Cash Flow Related to   HTML     37K 
                Leases (Details)                                                 
16: R52         LEASES LEASES - Supplemental Balance Sheet Related  HTML     59K 
                to Leases (Details)                                              
39: R53         LEASES - Future Minimum Lease Payments Under        HTML    101K 
                Noncancelable Leases - For Period Ending March 31,               
                2020 (Details)                                                   
67: R54         LEASES - Future Minimum Lease Payments Under        HTML    101K 
                Noncancelable Leases - For Period Ending December                
                31, 2019 (Details)                                               
59: R55         Income Taxes (Details)                              HTML     33K 
17: R56         STOCK-BASED COMPENSATION - Schedule of Expense      HTML     33K 
                (Details)                                                        
40: R57         STOCK-BASED COMPENSATION - Narrative (Details)      HTML     76K 
68: R58         STOCK-BASED COMPENSATION STOCK-BASED COMPENSATION   HTML     38K 
                - Assumptions used for options granted (Details)                 
57: R59         STOCK-BASED COMPENSATION - Option activity          HTML     58K 
                (Details)                                                        
18: R60         STOCK-BASED COMPENSATION - Restricted stock awards  HTML     48K 
                (Details)                                                        
26: R61         Loss Per Share (Details)                            HTML     46K 
75: R62         Related Party Transactions (Details)                HTML     94K 
46: R63         Commitments and Contingencies (Details)             HTML     24K 
20: R64         Certain Legal and Other Matters (Details)           HTML     57K 
28: R65         Changes in Ownership Interest in Consolidated       HTML     35K 
                Subsidiaries (Details)                                           
77: R66         Recent and Subsequent Events (Details)              HTML     47K 
47: XML         IDEA XML File -- Filing Summary                      XML    145K 
81: XML         XBRL Instance -- ara-3312020x10q_htm                 XML   1.99M 
73: EXCEL       IDEA Workbook of Financial Reports                  XLSX     93K 
 7: EX-101.CAL  XBRL Calculations -- ara-20200331_cal                XML    324K 
 8: EX-101.DEF  XBRL Definitions -- ara-20200331_def                 XML    608K 
 9: EX-101.LAB  XBRL Labels -- ara-20200331_lab                      XML   1.94M 
10: EX-101.PRE  XBRL Presentations -- ara-20200331_pre               XML   1.09M 
 6: EX-101.SCH  XBRL Schema -- ara-20200331                          XSD    189K 
65: JSON        XBRL Instance as JSON Data -- MetaLinks              396±   600K 
42: ZIP         XBRL Zipped Folder -- 0001498068-20-000073-xbrl      Zip    332K

‘R17’ — Income Taxes

This is an IDEA Financial Report. [ Alternative Formats ]

INCOME TAXES	3 Months Ended
INCOME TAXES	Mar. 31, 2020
Income Tax Disclosure [Abstract]
INCOME TAXES	INCOME TAXES The income tax expense included in the accompanying Consolidated Statements of Operations principally relates to the Company’s proportionate share of the pre-tax income of its joint venture subsidiaries. The determination of income tax expense for interim reporting purposes is based upon the estimated effective tax rate for the year adjusted for the impact of any discrete items which are accounted for in the period in which they occur. In prior years, the Company established a valuation allowance for certain deferred tax assets with respect to which the Company believes future taxable income levels would not be sufficient to realize the tax benefits. The Company’s effective income tax rate for the three months ended March 31, 2020 and 2019 were 61.7% and (15.8)%, respectively. These rates differ from the federal statutory rate of 21% principally due to the Company’s adoption of alternate tax methods as more fully described below, the portion of pre-tax income that is allocable to noncontrolling interests from the Company’s joint venture subsidiaries, which are pass-through entities for income tax purposes, the valuation allowance, as well as the change in fair value of the TRA liability, which is not deductible for income tax purposes, and also other non-deductible expenses. On March 27, 2020, the Coronavirus Aid, Relief, and Economic Security Act (the “CARES Act”) was enacted in response to the economic fallout of the 2020 coronavirus pandemic. The CARES Act increases the tax deduction for net operating losses from 80% to 100% for 2018 through 2020, allows net operating losses generated in 2018 through 2020 to be carried back up to five years and increases the deductible interest expense limit from 30% to 50% of taxable EBITDA. The CARES Act also permits the acceleration of tax depreciation related to certain classes of assets placed in service in prior years and increased the charitable contribution limitation from 10% to 25% for the year ended December 31, 2020. As a result of these statutory changes, during the three months ended March 31, 2020, the Company determined it will be able to carry its forecasted 2019 net operating losses of $15,338 back to tax years when the statutory tax rate was 35% resulting in an income tax benefit of $2,147, which is included in income tax benefit in the accompanying Consolidated Statements of Operations. As a result of the CARES Act, the Company released $3,250 of valuation allowance during the three months ended March 31, 2020. The Company continues to evaluate the impact of the CARES Act and takes into consideration the impact it may have on its overall tax provision.

Dates Referenced Herein and Documents Incorporated by Reference

This ‘10-Q’ Filing	Date	Other Filings

	12/31/20
Filed on:	5/11/20	3, 4, 8-K
For Period end:	3/31/20
	3/27/20
	3/31/19	10-Q, NT 10-Q
		List all Filings

2 Subsequent Filings that Reference this Filing

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

12/15/20  American Renal Assocs Holdin… Inc DEFM14A    12/15/20    1:3.7M                                   Broadridge Fin’l So… Inc
11/24/20  American Renal Assocs Holdin… Inc PREM14A    11/24/20    1:3.7M                                   Broadridge Fin’l So… Inc

↑Top

Filing Submission 0001498068-20-000073 – Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)

American Renal Associates Holdings, Inc. – ‘10-Q’ for 3/31/20 – ‘R17’

On: Monday, 5/11/20, at 4:16pm ET · For: 3/31/20 · Accession #: 1498068-20-73 · File #: 1-37751

Previous ‘10-Q’: ‘10-Q’ on 11/5/19 for 9/30/19 · Next: ‘10-Q’ on 8/10/20 for 6/30/20 · Latest: ‘10-Q’ on 11/6/20 for 9/30/20 · 2 References:

Quarterly Report — Form 10-Q — Sect. 13 / 15(d) – SEA’34
Filing Table of Contents

‘R17’ — Income Taxes

This is an IDEA Financial Report. [ Alternative Formats ]

Dates Referenced Herein and Documents Incorporated by Reference

2 Subsequent Filings that Reference this Filing

American Renal Associates Holdings, Inc. – ‘10-Q’ for 3/31/20 – ‘R17’

On: Monday, 5/11/20, at 4:16pm ET · For: 3/31/20 · Accession #: 1498068-20-73 · File #: 1-37751

Quarterly Report — Form 10-Q — Sect. 13 / 15(d) – SEA’34Filing Table of Contents

‘R17’ — Income Taxes

This is an IDEA Financial Report. [ Alternative Formats ]

Dates Referenced Herein and Documents Incorporated by Reference

2 Subsequent Filings that Reference this Filing

Quarterly Report — Form 10-Q — Sect. 13 / 15(d) – SEA’34
Filing Table of Contents